SCHEMBL20767804

SCHEMBL20767804

COc1cccc(OC)c1-n1c(NS(=O)(=O)C(C)C(OC)C2CC(C)(C)C2)nnc1-c1cncc(C)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
APLNR P35414 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18246853 1.00 APLNR (1.00) APLNR
SCHEMBL18246183 1.00 APLNR (1.00) APLNR
SCHEMBL18246338 1.00 APLNR (1.00) APLNR
SCHEMBL18245983 1.00 APLNR (1.00) APLNR
SCHEMBL19425874 0.94 APLNR (0.89) APLNR
SCHEMBL18246302 0.90 APLNR (1.00) APLNR
SCHEMBL18246337 0.90 APLNR (1.00) APLNR
SCHEMBL21097433 0.90 APLNR (1.00) APLNR
SCHEMBL28460421 0.90 APLNR (1.00) APLNR
SCHEMBL18246449 0.90 APLNR (1.00) APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3300500-B9 TRIAZOLE AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2021-01-13 EP disclosed
EP-3300500-B1 TRIAZOLE AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2020-02-26 EP disclosed
US-10221162-B2 Triazole agonists of the APJ receptor AMGEN INC. (US) 2019-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221162-B2 Triazole agonists of the APJ receptor TBXA2R, AGTR1, AGTR2 APLNR 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.